Burkitt Lymphoma

Observed

← altered in cohorts of

VPS35

67 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ORC6

66 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TPTE

66 / 263 cases (25 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MYLK3

62 / 263 cases (24 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

IGLL5

60 / 263 cases (23 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C16orf87

56 / 263 cases (21 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PTPRC

50 / 263 cases (19 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZNF280B

48 / 263 cases (18 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZNF280A

47 / 263 cases (18 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GGTLC2

46 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRAME

46 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MYC

45 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

OR11H12

44 / 263 cases (17 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ATP6V1G3

43 / 263 cases (16 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF6

43 / 263 cases (16 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD84

40 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ENSA

40 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ADAMTSL4

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C1orf56

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD48

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CDC42SE1

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GABPB2

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GOLPH3L

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MLLT11

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TARS2

39 / 263 cases (15 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ANXA9

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ARNT

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

BNIPL

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTSK

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTSS

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CTXND2

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ECM1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FAM243B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

HORMAD1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

KCNE1B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MCL1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MINDY1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRUNE1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF1

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SLAMF7

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SMIM11B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SMIM34B

38 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CERS2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GPT2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

LYSMD1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RPRD2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SCNM1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SEMA6C

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SETDB1

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TMOD4

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TNFAIP8L2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

VANGL2

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

VPS72

37 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL4

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NEK7

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PIP5K1A

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PRPF3

36 / 263 cases (14 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

APH1A

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

C1orf54

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CA14

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CIART

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL2

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL3

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCRL5

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MRPS21

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NCSTN

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NHLH1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SERPINC1

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

SYT11

35 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GPR52

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RABGAP1L

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RC3H1

34 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ANP32E

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD5L

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

COPA

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DARS2

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

GON4L

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PGM5

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PSMD4

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZBTB37

33 / 263 cases (13 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

APOA2

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DAP3

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DCAF8

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

DNAJA2

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

FCER1G

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

LY9

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

MSTO1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

NR1I3

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

PEX19

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

RCSD1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TMEM252

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

TOMM40L

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

YY1AP1

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ZNF687

32 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

CD244

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

ITLN1

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

← altered in cohorts of

USP21

31 / 263 cases (12 %) · ssm · CGCI-BLGSP

—

Observed

Burkitt Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 80show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall_molecule 48 trials (14 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	48	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal_antibody 44 trials (8 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	44	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall_molecule 34 trials (6 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall_molecule 30 trials (10 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall_molecule 19 trials (6 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall_molecule 17 trials (6 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall_molecule 17 trials (9 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Methotrexatesmall_molecule 15 trials (2 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 14 trials (3 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 12 trials (3 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 10 trials (2 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Vorinostatsmall molecule 9 trials (0 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Burkitt Lymphoma	8	Observed	clinicaltrials	graph →

Burkitt Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 80show all (up to 200)

→ investigated in trials for

Cyclophosphamidesmall_molecule

48 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rituximabmonoclonal_antibody

44 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall_molecule

34 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Etoposidesmall_molecule

30 trials (10 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vincristinesmall_molecule

19 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall_molecule

17 trials (6 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Prednisonesmall_molecule

17 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Methotrexatesmall_molecule

15 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cytarabinesmall molecule

14 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lenalidomidesmall molecule

12 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

10 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vorinostatsmall molecule

9 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Busulfansmall molecule

8 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

8 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dexamethasonesmall molecule

8 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

Burkitt Lymphoma studied in …STUDIED_INderived10 of 247show all (up to 200)
→ studied in	NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07819396Phase 2 · not yet recruiting Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06927466Phase 1 · recruiting A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)	—	—	Adult Burkitt Lymphoma	1	Observed	clinicaltrials	graph →

Burkitt Lymphoma studied in …STUDIED_INderived10 of 247show all (up to 200)

→ studied in

NCT03223610Phase 1/Phase 2 · recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT02992522Phase 1 · active not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT03015896Phase 1/Phase 2 · completed

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT06395103Phase 1/Phase 2 · recruiting

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT07819396Phase 2 · not yet recruiting

Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT04464200Phase 1 · active not recruiting

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT05389423Phase 1 · recruiting

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT07724457Phase 2/Phase 3 · not yet recruiting

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT06927466Phase 1 · recruiting

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Observed

→ studied in

NCT07662928Phase 2 · not yet recruiting

Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 247 trials mapped (52 active)

—

Adult Burkitt Lymphoma

Observed